TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01661556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole
Description: Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone
Description: Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
Study: NCT03937440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular block with 'rocunium®'
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
Study: NCT02678325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized high protein enteral nutrition
Description: A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized normal protein enteral nutrition
Description: double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
Study: NCT01518946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine HCl
Description: dose at the subject's current dose level
Study: NCT02074098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Direct Laryngoscope
Study: NCT01518946

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of matching placebo
Study: NCT02074098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Direct Laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope
Description: Videolaryngoscope-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope
Description: Videolaryngoscope-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airwayscope
Description: Videolaryngoscope-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airwayscope
Description: Videolaryngoscope-2
Study: NCT01198561

Intervention type: DEVICE
Intervention: repetitive Transcranial Magnetic Stimulation
Description: 10 times repetitive TMS, high frequency
Study: NCT02463929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Intravenous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
Study: NCT05556629

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT00780650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 80 mg oral dose, once per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg dose once per day for 6 weeks
Study: NCT04543617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab Matching Placebo
Description: Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab Matching Placebo
Description: Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT02875314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction
Description: vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Cycle Intensive Chemotherapy
Description: Carboplatin, thiotepa, etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandem 3 Cycle Intensive Chemotherapy
Description: Carboplatin, thiotepa
Study: NCT03672773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03224949

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw
Study: NCT01728792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection
Study: NCT01224925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping with Dycal
Description: Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping
Description: WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
Study: NCT04581421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carb Low Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carb Low Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb High Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb High Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
Study: NCT01203930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
Study: NCT03237858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartLogic ON
Description: Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HeartLogic OFF
Description: Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
Study: NCT02422719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: Radotinib 400mg bid
Study: NCT00245102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT04083716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Reference Formulation
Description: ABI-H2158 tablets Reference Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Reference Formulation
Description: ABI-H2158 tablets Reference Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Reference Formulation
Description: ABI-H2158 tablets Reference Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Test Formulation
Description: ABI-H2158 tablets Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Test Formulation
Description: ABI-H2158 tablets Test Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Test Formulation
Description: ABI-H2158 tablets Test Formulation
Study: NCT05604716

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT02463929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
Study: NCT02126683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study: NCT04016779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 will be administered once daily and compared to Placebo
Study: NCT04270409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical for: Solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or equivalent
Description: Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine or equivalent
Description: AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
Study: NCT01529008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core decompression/PREOB® implantation
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Study: NCT02996123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cad/cam maxillary dentures
Description: patients wearing cad/cam designed and milled dentures
Study: NCT01529008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Core decompression/placebo implantation
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
Study: NCT00231673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
Study: NCT02996123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cad/cam maxillary dentures
Description: patients wearing cad/cam designed and milled dentures
Study: NCT02878265

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A and ZInc
Description: Combination of vitamin A and zinc supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A , Zinc and Multivitamin
Description: Combination of vitamin A, zinc and multivitamins
Study: NCT03337178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blinded Fitbit
Description: Fitbit is worn for 3 months post-operatively with no activity feedback or step goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit is worn for 3 months post-operatively with feedback and step goals
Study: NCT02833415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [U-13C3] glycerol
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [U-13C3] glycerol
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Empagliflozin)
Description: Placebo tablet manufactured to mimic EMPA 10 mg tablet.
Study: NCT02098993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Study: NCT01255371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir
Description: Evaluation of second line antiretroviral regimen including boosted lopinavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Evaluation of second line antiretroviral regimen including boosted atazanavir
Study: NCT04516148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Dosing per hospital policy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Dosing per hospital policy
Study: NCT00491309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
Study: NCT02487784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block allograft
Description: A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Particulate allograft + autogenous bone chips
Description: The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
Study: NCT02215577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-situ split
Description: The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
Study: NCT01575652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group using angiotensin converting enzyme inhibitor
Description: Measurement of peritoneal protein loss level with use of ACEIs

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Group not using angiotensin converting enzyme inhibitor
Description: Measurement of peritoneal protein loss level without usage of ACEIs
Study: NCT01364688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral alfacalcidol
Description: Oral alfacalcidol 0.5 microgram per day

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: no drug
Description: no drug
Study: NCT03647579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine
Description: midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine
Description: Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
Study: NCT00594100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE Flow Reversal System (GFRS)
Description: Carotid artery angioplasty and stenting with embolic protection
Study: NCT03451994

Intervention type: OTHER
Intervention: Breath test
Description: Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.

Intervention type: OTHER
Intervention: Breath test
Description: Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
Study: NCT03451526

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries plus adjuvant chemotherapies or perioperative chemotherapies

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
Study: NCT03331848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331 - 20mg
Description: Oral
Study: NCT02215577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal embolization or ligation
Description: Portal vein embolization is performed according to the intervention used at the different sites.
Study: NCT04529148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dropping pills，best western medicine treatment
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment
Description: oral
Study: NCT03308448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
Study: NCT01643902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
Study: NCT03078751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth.
Study: NCT03308448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
Study: NCT02840383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: Schools not receiving intervention until two years after implementation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: intervention at the beginning of study.
Study: NCT02958215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml normal saline will be given before spinal anesthesia
Study: NCT02544464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose 1000 mg
Description: Ferric carboxymaltose is administered after anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (normal saline) is administered after anesthesia induction